1. Home
  2. CUBE vs TGTX Comparison

CUBE vs TGTX Comparison

Compare CUBE & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CubeSmart

CUBE

CubeSmart

HOLD

Current Price

$42.10

Market Cap

9.4B

Sector

Real Estate

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$49.81

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUBE
TGTX
Founded
2004
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
8.5B
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
CUBE
TGTX
Price
$42.10
$49.81
Analyst Decision
Buy
Strong Buy
Analyst Count
15
5
Target Price
$44.00
$49.80
AVG Volume (30 Days)
2.1M
2.2M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
5.34%
N/A
EPS Growth
N/A
1746.67
EPS
0.36
0.17
Revenue
$1,123,110,000.00
$2,785,000.00
Revenue This Year
$0.66
$49.08
Revenue Next Year
$2.82
$26.69
P/E Ratio
$116.53
$415.75
Revenue Growth
5.33
N/A
52 Week Low
$35.09
$25.37
52 Week High
$43.26
$59.30

Technical Indicators

Market Signals
Indicator
CUBE
TGTX
Relative Strength Index (RSI) 58.35 43.86
Support Level $38.78 $28.57
Resistance Level $42.71 $58.08
Average True Range (ATR) 0.80 2.42
MACD 0.01 -0.95
Stochastic Oscillator 63.41 38.37

Price Performance

Historical Comparison
CUBE
TGTX

About CUBE CubeSmart

CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: